Cargando…

Platelet thrombus formation in patients with end-stage renal disease before and after hemodialysis as measured by the total thrombus-formation analysis system

BACKGROUND: Patients with end-stage renal disease (ESRD) receiving hemodialysis (HD) often experience bleeding. However, mechanisms behind this bleeding tendency are incompletely understood but may involve platelet dysfunction. We, therefore, studied platelet-dependent thrombus formation in flowing...

Descripción completa

Detalles Bibliográficos
Autores principales: Mitic, Branka P., Dimitrijevic, Zorica M., Hosokawa, Kazuya, Cvetkovic, Tatjana P., Lazarevic, Milan V., Tasic, Danijela D., Jovanovic, Andriana, Jancic, Nina, Vrecic, Tamara, Ågren, Anna, Wallen, Håkan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9463292/
https://www.ncbi.nlm.nih.gov/pubmed/35366741
http://dx.doi.org/10.1007/s11255-022-03184-7
_version_ 1784787365883019264
author Mitic, Branka P.
Dimitrijevic, Zorica M.
Hosokawa, Kazuya
Cvetkovic, Tatjana P.
Lazarevic, Milan V.
Tasic, Danijela D.
Jovanovic, Andriana
Jancic, Nina
Vrecic, Tamara
Ågren, Anna
Wallen, Håkan
author_facet Mitic, Branka P.
Dimitrijevic, Zorica M.
Hosokawa, Kazuya
Cvetkovic, Tatjana P.
Lazarevic, Milan V.
Tasic, Danijela D.
Jovanovic, Andriana
Jancic, Nina
Vrecic, Tamara
Ågren, Anna
Wallen, Håkan
author_sort Mitic, Branka P.
collection PubMed
description BACKGROUND: Patients with end-stage renal disease (ESRD) receiving hemodialysis (HD) often experience bleeding. However, mechanisms behind this bleeding tendency are incompletely understood but may involve platelet dysfunction. We, therefore, studied platelet-dependent thrombus formation in flowing whole blood inside a microchip coated with collagen, and its association with circulating von Willebrand factor (VWF). METHODS: Blood samples were obtained in 22 patients before and after HD. The area under the 10 min flow pressure curve in a microchip (AUC10) reflecting total platelet thrombogenicity was measured, using the Total Thrombus-formation Analysis System (T-TAS01). AUC10 < 260 indicates platelet dysfunction. VWF activity and antigen in plasma were also assayed. RESULTS: VWF levels were moderately elevated and increased further after HD (P < 0.01 or lower). In contrast, AUC10 before and after HD was < 260 in 17/22 patients and < 130 in 15/22 patients, with no statistically significant difference in pre- vs post-HD measurements, indicating reduced platelet thrombogenicity, but with some variability as 5/22 patients showed normal platelet responsiveness. AUC10 and VWF activity or antigen levels in plasma were not correlated, either before or after HD. CONCLUSIONS: Most ESRD patients display moderate-to-severe platelet dysfunction as assessed by shear-induced platelet-dependent thrombus formation with T-TAS01. HD does not influence platelet function despite HD-induced elevations in VWF. T-TAS01 should be further evaluated as a tool in the assessment of bleeding risk in patients on HD. GRAPHICAL ABSTRACT: [Image: see text]
format Online
Article
Text
id pubmed-9463292
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Netherlands
record_format MEDLINE/PubMed
spelling pubmed-94632922022-09-11 Platelet thrombus formation in patients with end-stage renal disease before and after hemodialysis as measured by the total thrombus-formation analysis system Mitic, Branka P. Dimitrijevic, Zorica M. Hosokawa, Kazuya Cvetkovic, Tatjana P. Lazarevic, Milan V. Tasic, Danijela D. Jovanovic, Andriana Jancic, Nina Vrecic, Tamara Ågren, Anna Wallen, Håkan Int Urol Nephrol Nephrology - Original Paper BACKGROUND: Patients with end-stage renal disease (ESRD) receiving hemodialysis (HD) often experience bleeding. However, mechanisms behind this bleeding tendency are incompletely understood but may involve platelet dysfunction. We, therefore, studied platelet-dependent thrombus formation in flowing whole blood inside a microchip coated with collagen, and its association with circulating von Willebrand factor (VWF). METHODS: Blood samples were obtained in 22 patients before and after HD. The area under the 10 min flow pressure curve in a microchip (AUC10) reflecting total platelet thrombogenicity was measured, using the Total Thrombus-formation Analysis System (T-TAS01). AUC10 < 260 indicates platelet dysfunction. VWF activity and antigen in plasma were also assayed. RESULTS: VWF levels were moderately elevated and increased further after HD (P < 0.01 or lower). In contrast, AUC10 before and after HD was < 260 in 17/22 patients and < 130 in 15/22 patients, with no statistically significant difference in pre- vs post-HD measurements, indicating reduced platelet thrombogenicity, but with some variability as 5/22 patients showed normal platelet responsiveness. AUC10 and VWF activity or antigen levels in plasma were not correlated, either before or after HD. CONCLUSIONS: Most ESRD patients display moderate-to-severe platelet dysfunction as assessed by shear-induced platelet-dependent thrombus formation with T-TAS01. HD does not influence platelet function despite HD-induced elevations in VWF. T-TAS01 should be further evaluated as a tool in the assessment of bleeding risk in patients on HD. GRAPHICAL ABSTRACT: [Image: see text] Springer Netherlands 2022-04-02 2022 /pmc/articles/PMC9463292/ /pubmed/35366741 http://dx.doi.org/10.1007/s11255-022-03184-7 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Nephrology - Original Paper
Mitic, Branka P.
Dimitrijevic, Zorica M.
Hosokawa, Kazuya
Cvetkovic, Tatjana P.
Lazarevic, Milan V.
Tasic, Danijela D.
Jovanovic, Andriana
Jancic, Nina
Vrecic, Tamara
Ågren, Anna
Wallen, Håkan
Platelet thrombus formation in patients with end-stage renal disease before and after hemodialysis as measured by the total thrombus-formation analysis system
title Platelet thrombus formation in patients with end-stage renal disease before and after hemodialysis as measured by the total thrombus-formation analysis system
title_full Platelet thrombus formation in patients with end-stage renal disease before and after hemodialysis as measured by the total thrombus-formation analysis system
title_fullStr Platelet thrombus formation in patients with end-stage renal disease before and after hemodialysis as measured by the total thrombus-formation analysis system
title_full_unstemmed Platelet thrombus formation in patients with end-stage renal disease before and after hemodialysis as measured by the total thrombus-formation analysis system
title_short Platelet thrombus formation in patients with end-stage renal disease before and after hemodialysis as measured by the total thrombus-formation analysis system
title_sort platelet thrombus formation in patients with end-stage renal disease before and after hemodialysis as measured by the total thrombus-formation analysis system
topic Nephrology - Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9463292/
https://www.ncbi.nlm.nih.gov/pubmed/35366741
http://dx.doi.org/10.1007/s11255-022-03184-7
work_keys_str_mv AT miticbrankap plateletthrombusformationinpatientswithendstagerenaldiseasebeforeandafterhemodialysisasmeasuredbythetotalthrombusformationanalysissystem
AT dimitrijeviczoricam plateletthrombusformationinpatientswithendstagerenaldiseasebeforeandafterhemodialysisasmeasuredbythetotalthrombusformationanalysissystem
AT hosokawakazuya plateletthrombusformationinpatientswithendstagerenaldiseasebeforeandafterhemodialysisasmeasuredbythetotalthrombusformationanalysissystem
AT cvetkovictatjanap plateletthrombusformationinpatientswithendstagerenaldiseasebeforeandafterhemodialysisasmeasuredbythetotalthrombusformationanalysissystem
AT lazarevicmilanv plateletthrombusformationinpatientswithendstagerenaldiseasebeforeandafterhemodialysisasmeasuredbythetotalthrombusformationanalysissystem
AT tasicdanijelad plateletthrombusformationinpatientswithendstagerenaldiseasebeforeandafterhemodialysisasmeasuredbythetotalthrombusformationanalysissystem
AT jovanovicandriana plateletthrombusformationinpatientswithendstagerenaldiseasebeforeandafterhemodialysisasmeasuredbythetotalthrombusformationanalysissystem
AT jancicnina plateletthrombusformationinpatientswithendstagerenaldiseasebeforeandafterhemodialysisasmeasuredbythetotalthrombusformationanalysissystem
AT vrecictamara plateletthrombusformationinpatientswithendstagerenaldiseasebeforeandafterhemodialysisasmeasuredbythetotalthrombusformationanalysissystem
AT agrenanna plateletthrombusformationinpatientswithendstagerenaldiseasebeforeandafterhemodialysisasmeasuredbythetotalthrombusformationanalysissystem
AT wallenhakan plateletthrombusformationinpatientswithendstagerenaldiseasebeforeandafterhemodialysisasmeasuredbythetotalthrombusformationanalysissystem